Drugs / intratumoral injection of autologous CD1c (BDCA-1)+ myDC
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03707808 | Jan 2018 → Dec 2025 overdue | malignant soft tissue neoplasm | University Hospital Brussels | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | intratumoral injection of autologous CD1c (BDCA-1)+ myDC | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03707808 ↗ |
| Known as | myDC | “CD1c (BDCA-1)+ myeloid dendritic (myDC) cells will be obtained by immunomagnetic isolation from PBMC obtained by leukapheresis.” NCT03707808 ↗ |
| Modality | Cell therapy | “The investigators consider that the isolation represents a non-substantial manipulation of this somatic cell therapy product.” NCT03707808 ↗ |